• news.cision.com/
  • C-RAD/
  • Deliveries of C-RAD Catalysts with Elekta linear accelerators at European and U.S. cancer centers
English

Deliveries of C-RAD Catalysts with Elekta linear accelerators at European and U.S. cancer centers

Report this content

C-RAD and Elekta begin sales and marketing of C-RAD Catalyst and Sentinel systems. Customers show strong interest in the newly released Free Breathing Respiratory Gating Option.

 

The first installations of the C-RAD Catalyst System with Elekta’s new Versa HD® radiation therapy system have been delivered to two centers. The first European medical center to site the system is in Bordeaux, France; the system is equipped with C-RAD Catalyst and Sentinel 4D CT systems. The upgrade of respiratory gating will be installed during C-RAD’s fourth quarter.

 

The Edmonds, Washington hospital also elected to equip its new Versa HD® system with Catalyst, which has been delivered, including respiratory gating. The installation is ongoing.

 

Respiratory gated treatments based on free breathing are frequently used when the target volume is close to cardiac tissue or for special treatments in which tumor position depends on the respiratory cycle. The Catalyst and Sentinel system offer the required technology to perform such high end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery.

 

Tim Thurn, CEO of C-RAD AB:

 

“It has been a very positive and satisfying start of the cooperation between Elekta and C-RAD. The first installations took place immediately after the finalization of the joint validation. This interest from customers is a good sign. Further installations and deliveries from the order backlog will take place during our fourth quarter and the beginning of 2014. We are expecting that the new compatibility will contribute significantly to a successful second half in 2013.”

 

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 29 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.

For more information on C-RAD, please visit www.c-rad.com.

 

 

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com

Documents & Links